Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dueling for Duals: Why the Poorest Medicare Recipients Should be Pharma's Top Priority in 2006

This article was originally published in RPM Report

Executive Summary

The transfer of the poorest Medicare recipients to Part D means big changes in a critical submarket for pharma. If all goes well, it should pay off in a de facto price increase for some of the biggest industry blockbusters.

You may also be interested in...



Pfizer's Lipitor Sees Big Boost From Medicare

Pfizer is discounting its blockbuster brand Lipitor more aggressively. But, thanks to the economics of Medicare Part D, the product is still benefiting from a big net price increase in 2006. Lipitor's performance is some much needed good news for Pfizer--and maybe even better news for the industry as a whole.

Medicare Market Share: Drug Plan Starts With Big Four

Pharmaceutical manufacturers interested in maximizing their market share under the new Medicare drug benefit in 2006 should focus on four insurers likely to take the lion's share of enrollment. Dozens of plans are entering the market, but UnitedHealth Group, Wellpoint, Humana and Wellcare will start with a big edge in enrollment as of January 1. An analysis by The RPM Report explains why.

No More Generics? Implications Of The US Pricing Bill

Lilly’s view of the impact of the pending US drug pricing reform legislation is that it will require rethinking of all its small molecule development programs. That may sound extreme, but it is a logical response to the incentives in the bill. Does that mean the end of the generic drug era?

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS079614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel